Loncar Cancer Immunotherapy ETF News

Wall Street is set to wrap up the first quarter with strong gains. The gains were broad-based and well spread out across various segments.

Wall Street surged to close out February with the S&P 500 and Nasdaq Composite notching their best February since 2015.

The gains were broad-based and well spread out across various segments. We have highlighted some of the top performers in the ETF space from different sectors of the market.

A combination of factors, including a solid earnings season, a resilient economy and a technology surge, powered the rally, resulting in a gain of about 5% for the S&P 500 Index this year.

Range ETFs expanded its lineup on Wednesday to include four energy-related ETFs. They cover the coal, natural gas, oil services, and nuclear industries.

After a downbeat September, October too remained volatile for Wall Street due to higher rates.

While the ETF industry didn't see over-the-top activity, the past week was fairly busy, with 11 new ETFs making their debut and six ETFs shutting down. Among the launches were two covered call funds f

These sector ETFs have won and lost the most in the first half of 2023.

It was a busy week for ETF launches and closures. A total of 15 ETFs launched during the week shortened by the Juneteenth holiday, defying the typically slow launch count for weeks surrounding three-d

In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way wit

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.

Concerns over higher inflation and rising rates continued to weigh on investors' sentiments. This has provided a compelling opportunity for investors to buy cheap heading into 2023.

Biotech, the downtrodden segment of the market, has made a solid comeback on bargain hunting.

Pharma and biotech ETFs are in great shape and are trading at a one-month high level.